title: Inhibitory effects of intravenous lansoprazole 30 mg and pantoprazole 40 mg twice daily on intragastric acidity in healthy Chinese volunteers: a randomized, open-labeled, two-way crossover study.
abstract: BACKGROUND
  Until now there has been no study that directly compares the effect of lansoprazole and pantoprazole administered intravenously on intragastric acidity. The aim of this study is to compare the effect of lansoprazole (30 mg) and pantoprazole (40 mg) administered intravenously on gastric acidity.
  
  
  METHODS
  Helicobacter pylori-negative healthy volunteers were recruited in this open-label, randomized, two-way crossover, single centre study. Lansoprazole at 30 mg or pantoprazole at 40 mg was intravenously administered twice daily for 5 consecutive days with at least a 14-day washout interval. Twenty-four-hour intragastric pH was continuously monitored on days 1 and 5 of each dosing period.
  
  
  RESULTS
  Twenty-five volunteers completed the 2 dosing periods. The mean intragastric pH values were higher in subjects treated with lansoprazole than those with pantoprazole on both day 1 (6.41 ± 0.14 vs. 5.49 ± 0.13, P=0.0003) and day 5 (7.09 ± 0.07 vs. 6.64 ± 0.07, P=0.0002). Significantly higher percentages of time with intragastric pH >4 and pH >6 were found in the subjects treated with lansoprazole than those with pantoprazole on day 1 (pH >4, 87.12 ± 4.55% vs. 62.28 ± 4.15%, P=0.0012; pH >6, 62.12 ± 4.12% vs. 47.25 ± 3.76%, P=0.0216) and pH >6 on day 5 (76.79 ± 3.77% vs. 58.20 ± 3.77%, P=0.0025).
  
  
  CONCLUSIONS
  Intravenous lansoprazole produces a longer and more potent inhibitory effect on intragastric acidity than does intravenous pantoprazole.
authors.affiliation: Department of Gastroenterology, Changhai Hospital, 2nd Military Medical University, Shanghai, China.
authors.forename: Xian-Bao
authors.initials: XB
authors.lastname: Zhan
authors.forename: Xiao-Rong
authors.initials: XR
authors.lastname: Guo
authors.forename: Zhao-Shen
authors.initials: ZS
authors.lastname: Li
authors.forename: Yan-Fang
authors.initials: YF
authors.lastname: Gong
authors.forename: Jun
authors.initials: J
authors.lastname: Gao
authors.forename: Zhuan
authors.initials: Z
authors.lastname: Liao
authors.forename: Zhen
authors.initials: Z
authors.lastname: Li
authors.forename: Shen
authors.initials: S
authors.lastname: Gao
authors.forename: Pei
authors.initials: P
authors.lastname: Liu
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage*; D000328:Adult; D000897:Anti-Ulcer Agents / Q000008:administration & dosage*; D001483:Base Sequence; D002681:China; D018592:Cross-Over Studies; D017931:DNA Primers; D005260:Female; D005744:Gastric Acid; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007262:Infusions, Intravenous; D064747:Lansoprazole; D008297:Male; D000077402:Pantoprazole; D016133:Polymerase Chain Reaction; D012016:Reference Values
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D017931:DNA Primers; D064747:Lansoprazole; D000077402:Pantoprazole